MANHATTAN - The SEC is investigating "highly profitable and suspicious" purchases of call options for Martek Biosciences stock done in the days before Royal DSM announced it would buy all outstanding Martek shares at a 35% premium.
Categories / Uncategorized
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
Additional Reads
-
Federal judge rules against Texas in border barrier lawsuit against DHS November 30, 2023
-
-
FTC vs Facebook November 27, 2023 -
